Giampiero Capobianco1, Antonio Azzena2, Laura Saderi3, Francesco Dessole4, Salvatore Dessole4, Giovanni Sotgiu3. 1. Gynecologic and Obstetric Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100, Sassari, Italy. capobsass@tiscali.it. 2. Department of Obstetrics and Gynaecology, Conegliano Veneto Hospital, Conegliano, Veneto, Italy. 3. Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100, Sassari, Italy. 4. Gynecologic and Obstetric Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100, Sassari, Italy.
Abstract
INTRODUCTION AND HYPOTHESIS: The aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI). METHODS: A systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018. RESULTS: Eight full texts were evaluated but only five were selected for the qualitative and quantitative analyses. Duration of follow-up after Urolastic® injections was significantly heterogeneous, ranging from 6 to 24 months. Secondary injections were needed in 16.7%-35.0% of the treated patients. The pooled proportion of secondary injections was 20% (95% CI: 15%-24%; I2: 0%). Subjective improvement, measured by different means (i.e., patient global impression of improvement PGI-I score) was only assessed by 40% of the selected papers and was > 80% in two cohorts. The objective treatment success was evaluated by four (80.0%) papers and was achieved in all cohorts with a wide proportional range: from 32.7% (i.e., patients without objective SUI symptom cough tests and with a negative pad test) to 67.0%. Its pooled proportion was 57% (95% CI: 38%-75%; I2: 82.3%). CONCLUSIONS: Urolastic® showed effectiveness in patients with SUI during a follow-up period of 6-24 months.
INTRODUCTION AND HYPOTHESIS: The aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI). METHODS: A systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018. RESULTS: Eight full texts were evaluated but only five were selected for the qualitative and quantitative analyses. Duration of follow-up after Urolastic® injections was significantly heterogeneous, ranging from 6 to 24 months. Secondary injections were needed in 16.7%-35.0% of the treated patients. The pooled proportion of secondary injections was 20% (95% CI: 15%-24%; I2: 0%). Subjective improvement, measured by different means (i.e., patient global impression of improvement PGI-I score) was only assessed by 40% of the selected papers and was > 80% in two cohorts. The objective treatment success was evaluated by four (80.0%) papers and was achieved in all cohorts with a wide proportional range: from 32.7% (i.e., patients without objective SUI symptom cough tests and with a negative pad test) to 67.0%. Its pooled proportion was 57% (95% CI: 38%-75%; I2: 82.3%). CONCLUSIONS: Urolastic® showed effectiveness in patients with SUI during a follow-up period of 6-24 months.
Authors: Allert M de Vries; Hendrikje M K van Breda; Jimmy G Fernandes; Pieter L Venema; John P F A Heesakkers Journal: Urol Int Date: 2017-02-03 Impact factor: 2.089
Authors: Claudia R Kowalik; Fenne M Casteleijn; Hugo W F van Eijndhoven; Sandra E Zwolsman; Jan-Paul W R Roovers Journal: Neurourol Urodyn Date: 2017-04-28 Impact factor: 2.696
Authors: Konrad Futyma; Paweł Miotła; Krzysztof Gałczyński; Włodzimierz Baranowski; Jacek Doniec; Agnieszka Wodzisławska; Maciej Jóźwik; Małgorzata Oniszczuk; Tomasz Rechberger Journal: Biomed Res Int Date: 2015-04-20 Impact factor: 3.411